Journal of the American Animal Hospital Association · 2000 · 82 citations · 17 references
MedicineOncologyVeterinary OncologyChemotherapySurgical OncologyTumor PathologyChemotherapy In Veterinary SpeciesCombination ChemotherapyVeterinary ChemotherapyVeterinary VaccinationVeterinary VaccinesAnthracycline-based ChemotherapyAnticancer ChemotherapyChemotherapy Response AssessmentDoxorubicin-based TherapyFeline Cancer ModelsProgressive Disease AssessmentProgressive Disease QuantificationTumor Burden Measurement
A retrospective evaluation was performed on 12 cats with nonresectable, histopathologically confirmed fibrosarcomas that were treated with doxorubicin and cyclophosphamide chemotherapy. All of the tumors were located in sites potentially used for vaccination. Six cats had a greater than 50% decrease in gross tumor burden. However, the responses were not durable, with a median response duration of 125 days. All cats developed progressive disease. When animals that received other treatments after doxorubicin-based chemotherapy were eliminated from the analysis, median survival time was significantly longer for cats that responded to chemotherapy compared with the median survival time for nonresponders (242 and 83 days, respectively). These findings may serve as a basis for further evaluating the role of chemotherapy in the treatment of vaccine-associated sarcomas.
17
Philip H. Kass, William G. Barnes, W. L. Spangler et al. · Journal of the American Veterinary Medical Association · 1993 · 256 citations · Full text
Veterinary Medicine, Veterinary Epidemiology, Veterinary Oncology +16
Mattie J. Hendrick, Frances S. Shofer, Michael H. Goldschmidt et al. · Journal of the American Veterinary Medical Association · 1994 · 169 citations · Full text